Canaccord Genuity Reiterates a 'Buy' on Vivus (VVUS); FDA Request Creates Delay, But We Remain Favorable on Qnexa Overall
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Vivus (NASDAQ: VVUS), PT $15.
Canaccord analyst says, "While the delay is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "While the delay is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
